Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | RGS12 | O14924 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513799 | 1.00 | KDM4E (0.59) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL29141538 | 0.92 | KDM4E (0.51) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL27125031 | 0.88 | KDM4E (0.57) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL9952323 | 0.88 | KDM4E (0.57) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL6046185 | 0.88 | KDM4E (0.57) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL16064338 | 0.86 | KDM4E (0.42) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL25471322 | 0.85 | KDM4E (0.54) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL1527383 | 0.84 | USP2 (0.51) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL9847979 | 0.84 | KDM4E (0.53) | KDM4EUSP2HIF1AALOX15HSD17B10 | |
| SCHEMBL9848000 | 0.84 | KDM4E (0.53) | KDM4EUSP2HIF1AALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242053-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-07-31 | — | — | US | disclosed |
| US-20250136651-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-05-01 | — | — | US | disclosed |
| CN-117279889-B | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2025-04-25 | — | — | CN | disclosed |
| EP-4514980-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023114816-A9 | RECOMBINANT OPTIMIZED GALC CONSTRUCTS AND METHODS FOR TREATING GALC-ASSOCIATED DISORDERS | NEUROGENE INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119301258-A | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders | 爱丁堡大学董事会 | 2025-01-10 | — | — | CN | disclosed |
| EP-4473121-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2024-12-11 | — | — | EP | disclosed |
| CN-118696126-A | Recombinant optimized MECP2 cassettes and methods for treating Rate syndrome and related disorders | 爱丁堡大学董事会 | 2024-09-24 | — | — | CN | disclosed |
| CN-117279889-A | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023208081-A1 | SUBSTITUTED FLUOROSULFATE AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-11-02 | — | — | WO | disclosed |
| WO-2014159546-A1 | MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140193880-A1 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8632765-B2 | Modified factor VIII and factor IX genes and vectors for gene therapy | Asklepios Biopharmaceuticals, Inc. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130004462-A1 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | AskBio Inc. | 2013-01-03 | — | — | US | disclosed |
| US-8198421-B2 | Modified factor VIII and factor IX genes and vectors for gene therapy | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100284971-A1 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2037892-A2 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | Asklepios Biopharmaceutical, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007149852-A2 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KDM4E 2053/4885USP2 3792/4885HIF1A 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.